Britto Anna V, Schenka André A, Moraes-Schenka Natália G, Alvarenga Marcelo, Shinzato Júlia Y, Vassallo José, Ward Laura S
Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, School of Medical Sciences, State University of Campinas, São Paulo, Brazil.
BMC Cancer. 2009 Apr 8;9:109. doi: 10.1186/1471-2407-9-109.
Sentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the management of early breast cancer. When SLN is free of metastasis, complete axillary dissection may be skipped for staging in clinically N0 patients, allowing a more conservative procedure. Histological tumor features that could reliably predict SLN status have not yet been established. Since the degree of tumor lymphangiogenesis and vascularization may theoretically be related to the risk of lymph node metastasis, we sought to evaluate the relationship between lymph vessel invasion (LVI), lymphatic microvascular density (LVD), microvascular density (MVD) and VEGF-A expression, with SLN status and other known adverse clinical risk factors.
Protein expression of D2-40, CD34, and VEGF-A was assessed by immunohistochemistry on paraffin-embedded sections of primary breast cancer specimens from 92 patients submitted to SLN investigation. The presence of LVI, the highest number of micro vessels stained for D2-40 and CD34, and the protein expression of VEGF-A were compared to SLN status, clinicopathological features and risk groups.
LVI was detected in higher ratios by immunostaining with D2-40 (p < 0.0001), what would have changed the risk category from low to intermediate in four cases (4.3%). There was no association between LVI and other angiogenic parameters determined by immunohistochemistry with SLN macrometastases, clinical features or risk categories.
Assessment of LVI in breast carcinoma may be significantly increased by immunostaining with D2-40, but the clinical relevance of altering the risk category using this parameter may not be advocated according to our results, neither can the use of LVI and LVD as predictors of SLN macrometastasis in early breast cancer.
前哨淋巴结(SLN)活检是早期乳腺癌治疗中广泛应用的诊断方法。当SLN无转移时,临床上N0患者可不必进行完整腋窝淋巴结清扫分期,从而采用更保守的手术方式。目前尚未确立能够可靠预测SLN状态的组织学肿瘤特征。由于肿瘤淋巴管生成和血管生成程度理论上可能与淋巴结转移风险相关,我们试图评估淋巴管侵犯(LVI)、淋巴管微血管密度(LVD)、微血管密度(MVD)和VEGF - A表达与SLN状态及其他已知不良临床风险因素之间的关系。
通过免疫组织化学法评估92例行SLN检查的原发性乳腺癌标本石蜡包埋切片中D2 - 40、CD34和VEGF - A的蛋白表达。将LVI的存在情况、D2 - 40和CD34染色的微血管最高数量以及VEGF - A的蛋白表达与SLN状态、临床病理特征和风险分组进行比较。
通过D2 - 40免疫染色检测到LVI的比例更高(p < 0.0001),有4例(4.3%)患者的风险类别会因此从低风险变为中风险。LVI与通过免疫组织化学测定的其他血管生成参数、SLN大转移灶、临床特征或风险类别之间无关联。
用D2 - 40免疫染色评估乳腺癌中的LVI可能会显著增加,但根据我们的结果,不提倡使用该参数改变风险类别,在早期乳腺癌中也不能将LVI和LVD用作SLN大转移灶的预测指标。